cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.28437181.v1
title: Mpox vaccine acceptance and its predictors among people who have risky sexual practices: A systematic review and meta-analysis

description: Acceptance of available mpox vaccines among high-risk groups with risky sexual exposure varies by country, complicating efforts to draw conclusions and design effective intervention strategies. Seventeen studies were reviewed using the Joanna Briggs Institute (JBI) appraisal checklist from various databases. Funnel plot and I<sup>2</sup> test assessed publication bias and heterogeneity. DerSimonian and Laird random-effects model estimated the pooled mpox vaccine acceptance. Eggers and Beggs tests evaluated the small study effect, while subgroup and sensitivity analyses identified sources of heterogeneity. Globally, the pooled mpox vaccine acceptance rate among individuals with risky sexual practices was 75.22% (95% CI: 68.60, 81.84), indicating significant heterogeneity (I<sup>2</sup> = 99.83%, <i>p</i> &lt; .001). Significant predictors of higher acceptance included multiple sexual exposures and recent Sexually Transmitted Infections or Diseases (STI/STD) diagnoses. Despite higher acceptance rates among high-risk groups, many remain hesitant, posing challenges for outbreak control. Targeted campaigns and education on the importance of the mpox vaccine are essential. A PROSPERO registered systematic review and meta-analysis of literatures using PRISMA checklist on the global mpox vaccine acceptance and its predictors among people who have risky sexual practices. Vaccination is the key strategy, among multifaceted approaches, to ensure the safety of high-risk population groups, during outbreaks of international concern like mpox. However, vaccine acceptance among people who have risky sexual practices varies between nations. Therefore, making conclusions on their willingness to receive the mpox vaccine and designing intervention strategies is very difficult. The research team has used systematic collection and analysis of relevant findings reported by scholars globally to generate consolidated estimate of vaccine acceptance and identify influencing factors on which interventions are designed to increase vaccination coverage among people who have risky sexual practices. The total number of studies included in this review was 17, and all of them were conducted in countries where mpox cases are reported. Our analysis revealed that despite higher acceptance rates among people who have risky sexual practice, many remain hesitant, posing challenges for outbreak control. The current review identified and informed important focus areas of intervention including targeted vaccination campaigns and education on mpox vaccine.
DOI: 10.6084/m9.figshare.29532307
title: Vaccine hesitancy and economic hardship: A latent class analysis of racial and ethnic minority communities at high risk of COVID-19 infection in Southern California

description: We examined the association between economic hardship and vaccine hesitancy among communities at high risk of COVID-19 infection. We used latent class analysis to calculate the predicted probability of belonging in a high or low vaccine hesitancy group using nine vaccine belief and behavior survey items using data from clinical trial NCT05022472. An economic hardship index was constructed to assess whether experiencing one or more economic hardships during the COVID-19 pandemic was associated with high vaccine hesitancy using a multivariable logistic regression model. Overall, 39% of participants remained highly vaccine hesitant despite vaccine uptake exceeding 97%, highlighting the important distinction between uptake and hesitancy. Having experienced at least one economic hardship significantly increased the adjusted odds of high vaccine hesitancy, compared to not experiencing any economic hardships. Employment, infection history, education, and vaccine series completion factors were also salient factors associated with high vaccine hesitancy. Future research should explore the impact of targeted financial and policy interventions in fostering vaccine confidence.
DOI: 10.6084/m9.figshare.29532307.v1
title: Vaccine hesitancy and economic hardship: A latent class analysis of racial and ethnic minority communities at high risk of COVID-19 infection in Southern California

description: We examined the association between economic hardship and vaccine hesitancy among communities at high risk of COVID-19 infection. We used latent class analysis to calculate the predicted probability of belonging in a high or low vaccine hesitancy group using nine vaccine belief and behavior survey items using data from clinical trial NCT05022472. An economic hardship index was constructed to assess whether experiencing one or more economic hardships during the COVID-19 pandemic was associated with high vaccine hesitancy using a multivariable logistic regression model. Overall, 39% of participants remained highly vaccine hesitant despite vaccine uptake exceeding 97%, highlighting the important distinction between uptake and hesitancy. Having experienced at least one economic hardship significantly increased the adjusted odds of high vaccine hesitancy, compared to not experiencing any economic hardships. Employment, infection history, education, and vaccine series completion factors were also salient factors associated with high vaccine hesitancy. Future research should explore the impact of targeted financial and policy interventions in fostering vaccine confidence.
DOI: 10.6084/m9.figshare.29561763
title: A two-decade bibliometric analysis of tumor-associated macrophages in colorectal cancer research

description: Tumor-associated macrophages (TAMs), the predominant immune cells in the tumor microenvironment (TME), facilitate proliferation, invasion, metastasis, angiogenesis, chemoresistance, and immunosuppression in colorectal cancer (CRC). The mutual pathological mechanisms remain unclear, necessitating an in-depth study of the relationship between TAMs and CRC. This paper employs bibliometric methods to analyze TAMs and CRC research literature, aiming to assess current trends, evaluate the research status, and forecast future directions and emerging topics. We searched for publications published in the Web of Science Core Collection (WOSCC) database from January 1, 2001 to July 31, 2024. Following the establishment of specific search criteria for time, publication type, and language, bibliometric analysis and data visualization were conducted using Microsoft Excel, R software, VOSviewer, and CiteSpace. A total of 1,218 publications authored by 8,302 researchers across 61 countries and 1,657 institutions were analyzed. They were published in 427 journals, covering 4,451 keywords and citing 65,174 references. Keyword co-occurrence and literature co-citation analysis identified nuclear factor kappa-B, endothelial growth factor, angiogenesis, polarization, TME, immune response, programmed cell death protein 1 blockade, and metabolism as current research hotspots and trends in this field. Immune therapy and cancer-associated fibroblasts are key research areas, with the potential for further exploration of their mechanisms and targeted therapies. This paper employs bibliometric methods to comprehensively analyze and visualize research papers in TAMs and CRC. It analyzes the TAM-targeting research landscape in CRC, mapping current frontiers and translational potential to position TAMs as a promising immunotherapeutic strategy.
DOI: 10.6084/m9.figshare.29561763.v1
title: A two-decade bibliometric analysis of tumor-associated macrophages in colorectal cancer research

description: Tumor-associated macrophages (TAMs), the predominant immune cells in the tumor microenvironment (TME), facilitate proliferation, invasion, metastasis, angiogenesis, chemoresistance, and immunosuppression in colorectal cancer (CRC). The mutual pathological mechanisms remain unclear, necessitating an in-depth study of the relationship between TAMs and CRC. This paper employs bibliometric methods to analyze TAMs and CRC research literature, aiming to assess current trends, evaluate the research status, and forecast future directions and emerging topics. We searched for publications published in the Web of Science Core Collection (WOSCC) database from January 1, 2001 to July 31, 2024. Following the establishment of specific search criteria for time, publication type, and language, bibliometric analysis and data visualization were conducted using Microsoft Excel, R software, VOSviewer, and CiteSpace. A total of 1,218 publications authored by 8,302 researchers across 61 countries and 1,657 institutions were analyzed. They were published in 427 journals, covering 4,451 keywords and citing 65,174 references. Keyword co-occurrence and literature co-citation analysis identified nuclear factor kappa-B, endothelial growth factor, angiogenesis, polarization, TME, immune response, programmed cell death protein 1 blockade, and metabolism as current research hotspots and trends in this field. Immune therapy and cancer-associated fibroblasts are key research areas, with the potential for further exploration of their mechanisms and targeted therapies. This paper employs bibliometric methods to comprehensively analyze and visualize research papers in TAMs and CRC. It analyzes the TAM-targeting research landscape in CRC, mapping current frontiers and translational potential to position TAMs as a promising immunotherapeutic strategy.
DOI: 10.6084/m9.figshare.28521721
title: Expanding vaccination provider types and administration sites can increase vaccination uptake: A systematic literature review of the evidence in non-United States geographies

description: Vaccination is a successful public health intervention; however, vaccine-preventable diseases continue to pose global health risks due to insufficient uptake. Expanding authority for “alternative” or complementary healthcare providers to administer vaccinations, as well as approving additional non-clinical vaccination sites, could improve access to and uptake of vaccines. The value of complementary providers and expanded sites has been documented in the United States; however, there is limited evidence in geographies outside the United States. To address this gap, we conducted a systematic literature review to identify studies that evaluated vaccination by complementary providers and/or at expanded sites outside of the United States. Of 943 identified records, 18 met our inclusion criteria and were conducted in Australia (4), Canada (6), the United Kingdom (3), Peru (2), Cameroon (1), or in multiple geographies (2). All studies demonstrated that expanding provider types and sites could positively impact vaccine uptake and/or provide additional benefits.
DOI: 10.6084/m9.figshare.28521721.v1
title: Expanding vaccination provider types and administration sites can increase vaccination uptake: A systematic literature review of the evidence in non-United States geographies

description: Vaccination is a successful public health intervention; however, vaccine-preventable diseases continue to pose global health risks due to insufficient uptake. Expanding authority for “alternative” or complementary healthcare providers to administer vaccinations, as well as approving additional non-clinical vaccination sites, could improve access to and uptake of vaccines. The value of complementary providers and expanded sites has been documented in the United States; however, there is limited evidence in geographies outside the United States. To address this gap, we conducted a systematic literature review to identify studies that evaluated vaccination by complementary providers and/or at expanded sites outside of the United States. Of 943 identified records, 18 met our inclusion criteria and were conducted in Australia (4), Canada (6), the United Kingdom (3), Peru (2), Cameroon (1), or in multiple geographies (2). All studies demonstrated that expanding provider types and sites could positively impact vaccine uptake and/or provide additional benefits.
DOI: 10.6084/m9.figshare.29986126
title: Efficacy and safety of neoadjuvant treatment with chemotherapy and immune checkpoint blockades for potentially resectable gastric cancer: A retrospective study

description: The efficacy and safety of adding immune checkpoint inhibitors (ICIs) to neoadjuvant chemotherapy in patients with potentially resectable gastric cancer (GC) are uncertain. This study aimed to retrospectively evaluate the efficacy and safety of neoadjuvant ICIs plus chemotherapy in patients with potentially resectable GC. We retrospectively collected clinical data from patients with potentially resectable GC who received neoadjuvant treatment followed by gastrectomy at the Affiliated Hospital of Qingdao University from 2021 to 2023. The primary aim of this study was to investigate the differences in pathological tumor response (tumor regression grade, TRG) between neoadjuvant programmed cell death-(ligand)1 [PD-(L)1] blockade plus chemotherapy [neoadjuvant immunotherapy (IO) group] and chemotherapy alone (neoadjuvant chemotherapy group). Event-free survival (EFS) and treatment-related adverse events (TRAEs) were also observed. A total of 220 patients were retrospectively included in the analysis, among whom 96 (43.6%) received PD-(L)1 blockade plus chemotherapy as neoadjuvant treatment, and 124 (56.4%) received neoadjuvant chemotherapy. Higher pathological complete response (pCR) rate (21 of 96, 21.9% vs. 9 of 124, 7.2%, <i>P</i> = .004) and TRG0/1 rate (36 of 96, 37.5% vs. 22 of 124, 17.7%, <i>P</i> = .001) were detected in the neoadjuvant IO group. By the last follow-up, the median EFS time had not been reached in the two groups. The combined regimen of PD-(L)1 blockade plus chemotherapy was well-tolerated. In patients with potentially resectable GC, neoadjuvant ICIs plus chemotherapy resulted in higher pCR rates than did neoadjuvant chemotherapy alone. However, the difference in EFS rates was not statistically significant.
DOI: 10.6084/m9.figshare.29986126.v1
title: Efficacy and safety of neoadjuvant treatment with chemotherapy and immune checkpoint blockades for potentially resectable gastric cancer: A retrospective study

description: The efficacy and safety of adding immune checkpoint inhibitors (ICIs) to neoadjuvant chemotherapy in patients with potentially resectable gastric cancer (GC) are uncertain. This study aimed to retrospectively evaluate the efficacy and safety of neoadjuvant ICIs plus chemotherapy in patients with potentially resectable GC. We retrospectively collected clinical data from patients with potentially resectable GC who received neoadjuvant treatment followed by gastrectomy at the Affiliated Hospital of Qingdao University from 2021 to 2023. The primary aim of this study was to investigate the differences in pathological tumor response (tumor regression grade, TRG) between neoadjuvant programmed cell death-(ligand)1 [PD-(L)1] blockade plus chemotherapy [neoadjuvant immunotherapy (IO) group] and chemotherapy alone (neoadjuvant chemotherapy group). Event-free survival (EFS) and treatment-related adverse events (TRAEs) were also observed. A total of 220 patients were retrospectively included in the analysis, among whom 96 (43.6%) received PD-(L)1 blockade plus chemotherapy as neoadjuvant treatment, and 124 (56.4%) received neoadjuvant chemotherapy. Higher pathological complete response (pCR) rate (21 of 96, 21.9% vs. 9 of 124, 7.2%, <i>P</i> = .004) and TRG0/1 rate (36 of 96, 37.5% vs. 22 of 124, 17.7%, <i>P</i> = .001) were detected in the neoadjuvant IO group. By the last follow-up, the median EFS time had not been reached in the two groups. The combined regimen of PD-(L)1 blockade plus chemotherapy was well-tolerated. In patients with potentially resectable GC, neoadjuvant ICIs plus chemotherapy resulted in higher pCR rates than did neoadjuvant chemotherapy alone. However, the difference in EFS rates was not statistically significant.
DOI: 10.6084/m9.figshare.30490065
title: Mapping the evolution of immune checkpoint inhibitor research in small cell lung cancer: A bibliometric analysis (1997–2025)

description: Immune checkpoint inhibitors (ICIs) have revolutionized small cell lung cancer (SCLC) treatment, yet a comprehensive bibliometric analysis of global research trends is lacking. This study examines publication patterns, key contributors, and emerging research focuses on ICIs in SCLC using bibliometric tools. We analyzed 809 articles from the Web of Science Core Collection (1997–2025) with VOSviewer, CiteSpace, and Bibliometrix. Publications grew at 9.11% annually, with China (304 articles), the USA (201), and Japan (101) as top contributors. Leading institutions included the University of Texas System (105 articles) and UTMD Anderson Cancer Center (84). <i>Frontiers in Oncology</i> (38 articles) and <i>Thoracic Cancer</i> (32) were prominent journals. Key researchers were Wang J (21 articles, 1,706 citations) and Reck M (15 articles, 4,341 citations). Keyword analysis identified four clusters: (1) ICI mechanisms and immune-related molecules, (2) chemotherapy combinations, (3) clinical trial designs, and (4) ICI efficacy/safety. Burst terms included <i>overall survival</i>, <i>radiation therapy</i>, and <i>placebo</i>. Emerging trends highlight multimodal strategies, ICI-radiation synergy, and open-label trials. Research hotspots focus on ICI mechanisms, combination therapies, trial optimization, and safety. Future directions should explore predictive biomarkers, novel combinations, and tailored protocols to improve SCLC outcomes. This study provides a roadmap for advancing ICI research in SCLC, emphasizing global collaboration and translational innovation.
DOI: 10.6084/m9.figshare.30490065.v1
title: Mapping the evolution of immune checkpoint inhibitor research in small cell lung cancer: A bibliometric analysis (1997–2025)

description: Immune checkpoint inhibitors (ICIs) have revolutionized small cell lung cancer (SCLC) treatment, yet a comprehensive bibliometric analysis of global research trends is lacking. This study examines publication patterns, key contributors, and emerging research focuses on ICIs in SCLC using bibliometric tools. We analyzed 809 articles from the Web of Science Core Collection (1997–2025) with VOSviewer, CiteSpace, and Bibliometrix. Publications grew at 9.11% annually, with China (304 articles), the USA (201), and Japan (101) as top contributors. Leading institutions included the University of Texas System (105 articles) and UTMD Anderson Cancer Center (84). <i>Frontiers in Oncology</i> (38 articles) and <i>Thoracic Cancer</i> (32) were prominent journals. Key researchers were Wang J (21 articles, 1,706 citations) and Reck M (15 articles, 4,341 citations). Keyword analysis identified four clusters: (1) ICI mechanisms and immune-related molecules, (2) chemotherapy combinations, (3) clinical trial designs, and (4) ICI efficacy/safety. Burst terms included <i>overall survival</i>, <i>radiation therapy</i>, and <i>placebo</i>. Emerging trends highlight multimodal strategies, ICI-radiation synergy, and open-label trials. Research hotspots focus on ICI mechanisms, combination therapies, trial optimization, and safety. Future directions should explore predictive biomarkers, novel combinations, and tailored protocols to improve SCLC outcomes. This study provides a roadmap for advancing ICI research in SCLC, emphasizing global collaboration and translational innovation.
DOI: 10.6084/m9.figshare.30640056
title: Knowledge of the human papilloma virus and acceptance of its vaccine among male and female young adults in Jeddah, Saudi Arabia: A cross-sectional study

description: This study assessed university students’ awareness and knowledge of human papillomavirus (HPV) and its vaccine and willingness to accept vaccination in Jeddah, Saudi Arabia, and identified factors associated with these outcomes. This cross-sectional study was conducted in Jeddah, Saudi Arabia. The study population included university-level male and female students. During the first term of the 2023–2024 academic year, eligible participants were sent an online questionnaire. The study variables included measures of sociodemographic factors, awareness and knowledge of HPV and its vaccine, and vaccine acceptance. We conducted descriptive analysis of awareness, good knowledge, and willingness to accept vaccination, and multivariable logistic regression analyses to determine predictors of these outcomes. The study included 400 participants with a mean age of 21.4years, predominantly female and of Saudi nationality (93%). Awareness of HPV infection was reported by 49.3% of participants, while 44% were aware of the HPV vaccine. Among those aware of HPV, 82.2% recognized its link to cervical cancer, but misconceptions about HPV exist. Only 3.8% of participants had been vaccinated for HPV, and 33.5% expressed willingness to accept the vaccine. Age (per 1year increment; OR: 1.42, 95% CI: 1.25 to 1.62, <i>P</i> &lt; .001), mother’s education level (doctorate or advanced degree vs. pre-high school; OR: 4.65, 95% CI: 1.51 to 14.32, <i>P </i>= .007), and COVID-19 vaccine (received 3 doses vs.&lt;3; OR: 3.12, 95% CI: 1.78 to 5.45, <i>P</i> &lt; .001) were significant predictors of better HPV awareness. Living abroad was significantly associated with higher HPV vaccination rates (OR: 4.39, 95% CI: 1.27 to 15.1, <i>P </i>= .02). Male students were less likely to be willing to accept vaccination than females (OR: 0.38, 95% CI: 0.20 to 0.72, <i>P</i> = .003). HPV awareness, knowledge, and vaccine acceptance remain low among Saudi university students, with very limited uptake. Older age, maternal education, and prior COVID-19 vaccination were key predictors of awareness, highlighting important targets for future public health strategies. Targeted university-based and digital interventions are urgently needed to address these gaps and support national and regional HPV vaccination strategies. Future research should evaluate the effectiveness of such interventions and explore cultural and gender-specific barriers to HPV vaccine uptake.